Posts Tagged ‘patients’

var aid = 156; var v =”bOIuO3VMt7jIE08Jurgxxg%3d%3d”; var credomain = “app.engage.bidsystem.com”; document.write(”); Food Factor is a programme that gives you an expert advice on how you can lead a healthy lifestyle by just following simple moderations in your daily life. Different topics relating to health are covered in each episode. The tips given are really [...]

Tags : , , , , ,

var aid = 156; var v =”bOIuO3VMt7jIE08Jurgxxg%3d%3d”; var credomain = “app.engage.bidsystem.com”; document.write(”); CFI News Brief: Novel Treatment for Diabetes, Burn Victims and Lung Disease Patients OTTAWA, ONTARIO–(Marketwire – 12/09/10) – A renowned diabetes researcher at the University of Alberta (U of A) is embarking on a program that could revolutionize the treatment of diabetes worldwide. [...]

Tags : , , , , , , , , ,

var aid = 156; var v =”bOIuO3VMt7jIE08Jurgxxg%3d%3d”; var credomain = “app.engage.bidsystem.com”; document.write(”); Lorcaserin Phase 3 Clinical Trial In Patients With Type 2 Diabetes Shows Statistically Significant Weight Loss Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. reported that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight [...]

Tags : , , , , , , , , , , ,

var aid = 156; var v =”bOIuO3VMt7jIE08Jurgxxg%3d%3d”; var credomain = “app.engage.bidsystem.com”; document.write(”); Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with … Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company’s unique, investigational new drug for [...]

Tags : , , , , , , , , ,

var aid = 156; var v =”bOIuO3VMt7jIE08Jurgxxg%3d%3d”; var credomain = “app.engage.bidsystem.com”; document.write(”); Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added To Lantus(R) Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA® (exenatide) injection added [...]

Tags : , , , , , , , , , ,

var aid = 156; var v =”bOIuO3VMt7jIE08Jurgxxg%3d%3d”; var credomain = “app.engage.bidsystem.com”; document.write(”); Sensor-augmented insulin-pump therapy effective for type 1 diabetes patients Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes [...]

Tags : , , , , , ,